Alzheimers Weekly names ANAVEX 2-73 the number one most promising trial drug in Alzheimer's disease and Anavexs Phase I clinical program as "Trial
Sources News Release
Publisher: Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
Date Written: 11/01/2011
Year Published: 2011
Resource Type: Article
ANAVEX 2-73 has been named 2010s most promising trial drug by the editorial staff at Alzheimers Weekly.
Abstract: Hoboken, NJ January 6, 2011 - Anavex Life Sciences Corp. (Anavex, AVXL.OB) announced today that ANAVEX 2-73 has been named 2010s most promising trial drug by the editorial staff at Alzheimers Weekly. The publication selected the ANAVEX 2-73 trial from a field of over 100 trials that treat dementias such as Alzheimers and following the review of more than 10,000 articles. Staffers and clinical experts of Alzheimers Weekly said that Anavex stands out when scrutinized against their key cr...
To read the full release go to http://www.sources.com/Releases/NR1118.htm
© 2019. The information provided is copyright and may not be reproduced in any form or by any means (whether electronic, mechanical or photographic), or stored in an electronic retrieval system, without written permission of the publisher. The content may not be resold, republished, or redistributed. Indexing and search applications by Ulli Diemer and Chris DeFreitas.